AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03939780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F18]MK-6240
Description: Single radiotracer IV injection with subsequent emission scan
Study NCT03939780 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [F18]AV1451
Description: Single radiotracer IV injection with subsequent emission scan
Study NCT03702010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: spinal cord stimulation conventional
Description: If the patient has been assigned to the branch of the CME control group, after mapping the search for the pain zone, the neurostimulator is programmed to conventional stimulation.
Study NCT03702010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal cord stimulation experimental
Description: If the patient has been randomized to the branch of the EME experimental group, after a mapping of the search for the pain zone, a 90% subthreshold stimulation is programmed.
Study NCT02238912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kandhaga rasayanam
Description: KANDHAGA RASAYANAM is a siddha herbo mineral drug with sulphur as a sole mineral ingredient. It is chosen from the classic Siddha text Siddha Vaidhya Thirattu.
Study NCT04196140 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod Horizon™ Automated Glucose Control System
Description: The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery
Study NCT00885716 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient training in shared decision making
Study NCT00885716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training
Study NCT01477957 — intervention group
Intervention type: PROCEDURE
Intervention: surgery
Description: biliopancreatic diversion, gastric banding, gastric sleeve resection
Study NCT05024240 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Stabilometry
Description: Probands will stand on stabilometric platform (double leg stance) and we will measure CoP parameters area and length. We also make this task harder by using foam and exclusion of visual control. Length of one test is 30s.
Study NCT05024240 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stabilometry
Description: Probands will stand on stabilometric platform (double leg stance) and we will measure CoP parameters area and length. We also make this task harder by using foam and exclusion of visual control. Length of one test is 30s.
Study NCT05024240 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Stroop test
Description: There are various names of colours written in non-matching font colour in this test. During this test probands are required to name the colour which is written in text not the colour of the font. We will measure reaction time and number of mistakes.
Study NCT05024240 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stroop test
Description: There are various names of colours written in non-matching font colour in this test. During this test probands are required to name the colour which is written in text not the colour of the font. We will measure reaction time and number of mistakes.
Study NCT05024240 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Backward counting test
Description: In this counting test probands are given number from interval \<180-200> and they are asked to subtract 7 during 30s interval of the testing. We will measure reaction time and number of mistakes.
Study NCT05024240 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Backward counting test
Description: In this counting test probands are given number from interval \<180-200> and they are asked to subtract 7 during 30s interval of the testing. We will measure reaction time and number of mistakes.
Study NCT02942381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine Sulfate
Description: 200mg Bid (eGFR>60 ml/min/1.73m2 ), 100mg Tid(eGFR45-59 ml/min/1.73m2 ), 100mg Bid(eGFR 30-44 ml/min/1.73m2 )
Study NCT02942381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02247596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 1g tds 2 weeks
Study NCT02247596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill 1g tds for 2 weeks
Study NCT04510246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced case management
Description: The health care worker will offer support to the GP for all aspects of the cascade of hepatitis C care including:~* Further testing advice~* Awareness that treatment can be prescribed by the general practitioner~* Conducting pre-treatment work-up assessment~* DAA prescription guidelines, including linkage to specialist consultation~* Providing treatment support~* Advising on testing process for cure~* Advising on post-cure management including methods of follow-up to manage risks (e.g. harm minimisation, reducing re-infection risk, opioid substitution therapy)~* Linking GP to resources for patients with cirrhosis or other concerns to specialist support for ongoing management.~The GP will be offered the option of the DoH specialist to contact the patient directly with the GP's consent to notify them of their result and to educate them on testing and treatment options and referral back to their GP.
Study NCT03369834 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Red Light-emitting diode device
Description: The phototherapy will be applied for 3 days followed by a red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.
Study NCT03369834 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrared Light-emitting diode device
Description: The phototherapy will be applied for 3 days followed by a infrared LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.
Study NCT04604184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 764198
Description: BI 764198
Study NCT04604184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01813656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks
Study NCT01813656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
Study NCT01412541 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Uncoated Angioplasty Balloon
Description: Subjects will be randomized 2:1 to the Moxy Drug Coated Balloon or Standard Angioplasty Balloon
Study NCT01412541 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moxy Drug Coated Balloon
Description: Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
Study NCT02873390 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HerinCAR-PD1 cells
Description: herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
Study NCT01362634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trans-theoretical Process of Change Model-self
Description: self-administered, computer-based intervention
Study NCT03369834 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrared and Red Light-emitting diode device
Description: The phototherapy will be applied for 3 days followed by a infrared and Red LED blanket of 25x40 cm2, with equidistant distribution - 1 cm between them, with total energy per area of 180 J, bilaterally on the anterior tibial and triceps sural muscles, bilaterally. The intervention of these muscular groups is made possible by the distal involvement of diabetic polyneuropathy.~All LEDs will be checked at the beginning of the project in the Laboratory of Photophysics of the Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.
Study NCT03369834 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: LED device off.
Study NCT01362634 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trans-theoretical Process of Change Model - interviewer
Description: interviewer-administered intervention
Study NCT00978081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid hydrochloride
Description: Patients undergo continuous or fractionated photodynamic therapy.
Study NCT03686709 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Post therapy PET/CT Imaging
Description: whole-body PET/CT following Y90 radioembolization
Study NCT03932422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluate if the individuals are resistant hypertensive patients
Description: Evaluation of the individuals has the objective determine if they are resistant hypertensive patients. This is important because the resistant people have worse prognosis than the controlled people and need more attention from the health professionals. Analysis must be done using the ambulatory blood pressure monitoring.
Study NCT01827722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex
Description: Intravitreal injection of Ozurdex
Study NCT01827722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal Injection of Ranibizumab
Study NCT04198038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Songwriting with licensed music therapist
Description: Song selected by parent-child dyad with recordings of physiologic components (i.e. heartbeat, breathing)
Study NCT01431690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: A single 25 mg dose of warfarin
Study NCT01827722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Ozurdex with Ranibizumab PRN
Description: Intravitreal Injection of combination medication Ozurdex and Ranibizumab
Study NCT03342898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YF-17D
Description: YF-17D SC injection.
Study NCT03342898 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TDV
Description: TDV SC injection.
Study NCT01431690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omefas
Description: 4 x 1 g capsule dose of Epanova®
Study NCT01431690 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: omega-3-acid ethyl esters
Description: 4 x 1 g capsule dose of Lovaza®
Study NCT02697890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDBA (MinerOss®) + Mucograft® seal
Description: Collagen matrix membrane for soft-tissue regeneration
Study NCT02697890 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)
Description: Standard of Care
Study NCT00589134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gatorade Endurance Formula
Description: carbohydrate electrolyte beverage
Study NCT00589134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ganirelix acetate
Description: GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days.
Study NCT01211457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapacitabine and decitabine (Part 1 - completed)
Description: decitabine will be administered in alternating cycles with sapacitabine
Study NCT01211457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapacitabine and venetoclax (Part 2 - recruiting)
Description: sapacitabine will be administered concomitantly with venetoclax
Study NCT03124407 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin Topical Solution
Description: Over-the-counter Tentative Final Monograph compliant product with 0.25% capsaicin
Study NCT03124407 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drug product vehicle
Description: This is the vehicle for the active treatment drug product, but without capsaicin
Study NCT04546399 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D-CRT
Study NCT03342898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline (0.9% NaCl) SC injection.
Study NCT04546399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood, urine and cerebrospinal fluid collection
Study NCT04546399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study NCT03279536 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Oral lactoferrin
Description: Oral lactoferrin 120 mg twice /day and it's based on fast dissolving through direct swallowing per oral route with fruits flavor taste.
Study NCT03279536 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: TDI of LMW iron dextran
Description: Total Dose Infusion of LMW iron dextran up to 20mg/kg body weight is infused intravenously
Study NCT04572399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UV Light Treatment
Description: UV light therapy administered while patient is mechanically ventilated
Study NCT04186117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample before any treatment
Study NCT03930238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VA MapTrek
Description: The objective is to report activity levels in our virtual environment to Veterans, thereby encouraging them to walk more.
Study NCT01804686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent ibrutinib clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.
Study NCT03930238 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Only
Description: Fitbit Only
Study NCT02181751 — intervention group
Intervention type: OTHER
Intervention: Trauma Focused Cognitive Behavioural Therapy Group
Description: Youth may participate in trauma focused cognitive behavioural group therapy (TF-CBT)
Study NCT03296423 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination
Description: Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
Study NCT03296423 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
Study NCT03003884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: Initial dose plus supplemental doses as necessary.
Study NCT03003884 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Initial dose plus supplemental doses as necessary.
Study NCT01763489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applicability Assessment
Description: assess the applicability of a trial using the ASSIST tool or the synopsis
Study NCT01763489 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applicability Assessment
Description: assess the applicability of a trial using the ASSIST tool or the synopsis
Study NCT04422509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lanadelumab
Description: single dose, or two doses administered iv
Study NCT04422509 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: regular care
Description: no lanadelumab administration, treated according to regular care
Study NCT00825643 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation
Study NCT00421096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 125 mg/m² at day 1, 8, 15, 21 and 28, 2 hours before radiotherapy.
Study NCT00421096 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45Gy (5 x 1,8Gy/week) on pelvic area +/- boost (10 to 15Gy)~+/- 45Gy (5 x 1,8Gy/week)on lumbo-aortic area
Study NCT01535196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigantol oil and MCT oil
Description: Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
Study NCT01535196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vigantol oil and MCT oil
Description: Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
Study NCT00421096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg/m² at day 1, 8, 15, 21 and J28 before Gemcitabine and with a hyperhydration
Study NCT03881813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic retainers
Description: Orthodontic retainers were bonded on the lower teeth of the subjects after fixed orthodontic treatment and were evaluated for their effectiveness for the followup of one year.
Study NCT03139968 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: (sham) radiation absorbing drape (RADPAD®)
Study NCT03139968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: (sham) radiation absorbing drape (RADPAD®)
Study NCT01171066 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tasman CPAP system
Description: Participants will trial the Tasman CPAP system for a duration of 1 week in place of their current CPAP system.
Study NCT01762358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Khalifa's therapy
Description: One hour of Khalifa's therapy which is specially applied pressure to the skin
Study NCT01762358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Twelve times standardized Physiotherapy
Study NCT04623736 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: quitSTART
Description: All participants will have access to the Smokefree.gov Initiative smoking cessation smartphone application, quitSTART. This app is available, at no cost, to anyone who owns a smartphone and is interested in quitting smoking. All smokers who download quitSTART are asked to provide basic information about themselves (e.g., age, sex, reason to quit smoking, triggers to smoke, when users typically smoke, how users plan to celebrate success, smoking frequency, age when started smoking regularly, ethnicity, race, cigarettes smoked per day), and set a quit date. Information about cessation and challenges to help support quitting are available, as well as games and tracking features. While using the app, users can proactively report cigarette cravings, if they slipped, if they are feeling down or feeling great. If a user reports a craving, they have the option to mark the timing or location of the craving and request a reminder to resist future cravings at the same time or location.
Study NCT01386346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.
Study NCT01386346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
Study NCT01386346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 50 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
Study NCT01386346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 625 mg/m2 orally twice daily beginning on Day 3 or 5 and will be taken without interruption for each 21-day cycle.
Study NCT02767193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DCV3
Description: Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus.~Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4
Study NCT04546399 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration